Please assess the completion status of the following clinical trial:

Trial Title: X-82 to Treat Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in one or both eyes for at least 6 months prior to joining the study and has required at least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater than 6 weeks for the past two injections in the eye that is selected to be the study eye.~* Must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-VEGF injection at Screening Visit 1~* Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25 letters (20/320) or better in both eyes~Exclusion Criteria:~* Previous vitrectomy to the study eye within 30 days of Screening Visit 1~* Choroidal neovascularization (CNV) due to causes other than AMD~* Proliferative diabetic retinopathy in either eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 50 mg of X-82 plus ivt anti-VEGF prn (Type: EXPERIMENTAL): Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
- 100 mg of X-82 plus ivt anti-VEGF prn (Type: EXPERIMENTAL): Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
- 200 mg of X-82 plus ivt anti-VEGF prn (Type: EXPERIMENTAL): Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
- Placebo plus ivt anti-VEGF prn (Type: PLACEBO_COMPARATOR): Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).